Literature DB >> 35749047

Transcription factor p8 regulates autophagy in response to disulfiram via PI3K/mTOR/p70S6K signaling pathway in pancreatic cancer cells.

Zhangyu Yao1,2,3, Xiang Li1,2, Jun Gao1,2, Yutao Wang1,2, Linmei Xiao1,2, Xinxia Chang1,2, Fangzhou Liu3, Zhenqing Feng1,2, Xiao Zhang4,5.   

Abstract

Disulfiram (DSF), which is an inhibitor of aldehyde dehydrogenase (ALDH) and approved by the FDA for the treatment of alcoholism previously, has been repurposed for use as a cancer treatment because of its potent effect in preclinical studies. In this study, we found that disulfiram forms potent complexes with copper (DSF/Cu) inhibited cell proliferation, induced apoptosis in human pancreatic cancer cells, which was detected by flow cytometry and western blotting. Meanwhile, autophagy and autophagic flux also clearly observed by transmission electron microscopy, confocal microscopy and flow cytometry. Our results also showed that DSF/Cu induced transcription factor p8 upregulation and PI3K/mTOR signaling pathway activation detected by real-time PCR and western blotting. Additionally, suppression of p8 inactivated the mTOR signaling pathway and autophagic flux maintained. Furthermore, mechanism study indicated that autophagy induced by DSF/Cu was regulated by p8 and was related to PI3K/mTOR/p70S6K signaling pathway in pancreatic cancer cells. Our findings provide insights into the role of p8 in regulating autophagy induced by DSF/Cu effects in pancreatic cancer cells.
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.

Entities:  

Keywords:  Autophagy; Disulfiram; Pancreatic cancer; Transcription factor p8; mTOR

Mesh:

Substances:

Year:  2022        PMID: 35749047     DOI: 10.1007/s13577-022-00731-3

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.374


  42 in total

1.  5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.

Authors:  Min Geun Lee; Sang Hyub Lee; Seung June Lee; Yoon Suk Lee; Jin-Hyeok Hwang; Ji Kon Ryu; Yong-Tae Kim; Dong Uk Kim; Sang Myung Woo
Journal:  Chemotherapy       Date:  2014-01-18       Impact factor: 2.544

2.  Induction of autophagy-dependent apoptosis in cancer cells through activation of ER stress: an uncovered anti-cancer mechanism by anti-alcoholism drug disulfiram.

Authors:  Xiao Zhang; Pan Hu; Shi-Ying Ding; Ting Sun; Ling Liu; Shiwei Han; Albert B DeLeo; Ananthan Sadagopan; Wei Guo; Xinhui Wang
Journal:  Am J Cancer Res       Date:  2019-06-01       Impact factor: 6.166

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth.

Authors:  G V Mallo; F Fiedler; E L Calvo; E M Ortiz; S Vasseur; V Keim; J Morisset; J L Iovanna
Journal:  J Biol Chem       Date:  1997-12-19       Impact factor: 5.157

5.  5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

Authors:  Elias Assaf; Muriel Verlinde-Carvalho; Catherine Delbaldo; Julien Grenier; Zineb Sellam; Damien Pouessel; Linda Bouaita; Isabelle Baumgaertner; Iradj Sobhani; Claude Tayar; Muriel Paul; Stéphane Culine
Journal:  Oncology       Date:  2011-07-18       Impact factor: 2.935

6.  Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.

Authors:  Di Chen; Qiuzhi Cindy Cui; Huanjie Yang; Q Ping Dou
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

7.  Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties.

Authors:  N C Yip; I S Fombon; P Liu; S Brown; V Kannappan; A L Armesilla; B Xu; J Cassidy; J L Darling; W Wang
Journal:  Br J Cancer       Date:  2011-04-12       Impact factor: 7.640

8.  Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).

Authors:  H S Park; B Kang; H J Chon; H-S Im; C-K Lee; I Kim; M J Kang; J E Hwang; W K Bae; J Cheon; J O Park; J Y Hong; J H Kang; J H Kim; S H Lim; J W Kim; J-W Kim; C Yoo; H J Choi
Journal:  ESMO Open       Date:  2021-02-09

9.  A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram.

Authors:  Juan Cong; Yangyang Wang; Xiao Zhang; Nan Zhang; Ling Liu; Klara Soukup; Theodoros Michelakos; Theodore Hong; Albert DeLeo; Lei Cai; Francesco Sabbatino; Soldano Ferrone; Hang Lee; Vera Levina; Bryan Fuchs; Kenneth Tanabe; Keith Lillemoe; Cristina Ferrone; Xinhui Wang
Journal:  Cancer Lett       Date:  2017-08-30       Impact factor: 9.756

10.  Blocking the formation of radiation-induced breast cancer stem cells.

Authors:  Yangyang Wang; Wende Li; Shalin S Patel; Juan Cong; Nan Zhang; Francesco Sabbatino; Xiaoyan Liu; Yuan Qi; Peigen Huang; Hang Lee; Alphonse Taghian; Jian-Jian Li; Albert B DeLeo; Soldano Ferrone; Michael W Epperly; Cristina R Ferrone; Amy Ly; Elena F Brachtel; Xinhui Wang
Journal:  Oncotarget       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.